| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 11, 2026 |
| Accession Number: | 0001213900-26-052963 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 11, 2026 |
| Accession Number: | 0001213900-26-052963 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Company"), a leading developer of humanoid robots and AI systems designed for human interaction across enterprise and consumer environments, reports its interim financial results for the three and six months ended March 31, 2026 ("Q2-2026"). All dollar figures are reported in United States dollars ("USD"), unless otherwise stated. Q2-2026 Financial and Operating Highlights For the three and six months ended March 31, 2026, the Company generated revenue of $225,000 and $578,000, respectively, compared to $727,000 and $1,543,000 for the corresponding periods in the prior fiscal year. The decline in revenue i
CINCINNATI, Ohio, May 19, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology, today announced that its Board of Directors (the "Board of Directors" or "Board") has approved a 1-for-10 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on May 21, 2026. On April 30, 2026, Onconetix held a special meeting of stockholders (the "Special Meeting"), at which the Company's stockholders approved a proposal to effect one or more reverse splits, at a ratio in the range of
Transaction to take Realbotix LLC, a premier social humanoid robot company, to the Nasdaq Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Parent Company"), a leading AI humanoid robot manufacturer for social tasks, is pleased to provide an update on its previously announced transaction to list Realbotix LLC ("RealLLC" or the "Subsidiary"), a wholly owned subsidiary of Realbotix, on the Nasdaq Capital Market via a reverse takeover transaction with Onconetix, Inc. (NASDAQ:ONCO) ("ONCO"). The proposed transaction will result in the robotics and AI business of RealLLC to be listed on Nasdaq, with the Parent Company (Realbotix) maintaining a 75–90% ownership
4 - Onconetix, Inc. (0001782107) (Issuer)
4 - Onconetix, Inc. (0001782107) (Issuer)
4 - Onconetix, Inc. (0001782107) (Issuer)
8-K - Onconetix, Inc. (0001782107) (Filer)
8-K - Onconetix, Inc. (0001782107) (Filer)
10-Q - Onconetix, Inc. (0001782107) (Filer)
Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising
Realbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Company"), a leading developer of humanoid robots and AI systems designed for human interaction across enterprise and consumer environments, reports its interim financial results for the three and six months ended March 31, 2026 ("Q2-2026"). All dollar figures are reported in United States dollars ("USD"), unless otherwise stated. Q2-2026 Financial and Operating Highlights For the three and six months ended March 31, 2026, the Company generated revenue of $225,000 and $578,000, respectively, compared to $727,000 and $1,543,000 for the corresponding periods in the prior fiscal year. The decline in revenue i
SC 13G - Onconetix, Inc. (0001782107) (Subject)
SC 13D - Onconetix, Inc. (0001782107) (Subject)
SC 13D - Onconetix, Inc. (0001782107) (Subject)